Table 4 Subgroup analysis of prior cancer history impact on overall survival stratified by the time interval in matched cohort

Without prior cancer

4380

33.0(32.9–33.2)

18.2(18.1–18.4)

11.7(11.6–11.8)

4380

33.0(32.9–33.2)

18.2(18.1–18.4)

11.7(11.6–11.8)

Prostate cancer

44

42.9(42.8–43.0)

28.6(28. 5–28.7)

9.5(9.4–9.6)

0.905(0.670–1.220)

0.520

82

24.4(24.3–24.5)

11.3(11.2–11.4)

5.6(5.5–5.7)

1.249(0.956–1.632)

0.058

Breast cancer

25

100.0

53.9(53.7–54.1)

47.9(47.7–48.1)

0.309(0.228–0.420)

< 0.001

85

12.8(12.7–12.9)

2.7(2.7–2.7)

2.7(2.7–2.7)

1.489(1.115–1.987)

< 0.001

Renal and bladder cancer

23

33.1(32.9–33.3)

26.5(26.3–26.7)

0.0

1.073(0.645–1.785)

0.769

28

37.8(37.6–38.0)

18.9(18.8–19.0)

14.2(14.1–14.3)

0.904(0.612–1.340)

0.617

Colon and rectal cancer

20

40.0(39.8–40.2)

12.0(11.8–12.2)

12.0(11.8–12. 2)

0.941(0.593–1.494)

0.795

23

21.7(21.5–21. 9)

17.4(17.2–17.6)

11.6(11.5–11.7)

1.300(0.789–2.150)

0.219

Uterine cancer

3

66.7(66.2–67.2)

66.7(66.2–67.2)

66.7(66.2–67.2)

0.377(0.113–1.257)

0.291

21

37.8(37.6–38.0)

32.4(32.2–32.6)

NA

0.719(0.453–1.143)

0.216

Lung cancer

8

62.5(62.2–62.8)

15.6(15.3–15.9)

0.0

0.751(0.395–1.429)

0.430

8

37.5(37.2–37.8)

18.8(18.5–19.1)

18.8(18.5–19.1)

0.958(0.464–1.980)

0.906

Small intestinal cancer

6

25.0(24.6–25.4)

25.0(24.6–25.4)

25.0(24.6–25.4)

1.180(0.406–3.400)

0.737

9

55.6(55.3–55.9)

0.0

0.0

0.804(0.413–1.560)

0.547

Oral cancer

3

100.0

33.3(32.8–33.8)

33.3(32.8–33.8)

0.441(0.175–1.106)

0.216

10

47.6(47.3–47.9)

19.0(18.8–19.2)

0.0

0.964(0.524–1.773)

0.904

Gastric cancer

7

21.4(21.1–21.7)

0.0

0.0

1.274(0.516–3.145)

0.535

5

60.0(59.8–60.4)

30.0(29.5–30.5)

30.0(29.5–30.5)

0.852(0.299–2.421)

0.772

Hepatocellular cancer

6

33.3(32.9–33.7)

16.7(16.4–17.0)

16.7(16.4–17.0)

0.942(0.402–2.206)

0.889

2

50.0(49.3–50.7)

0.0

0.0

1.101(0.257–4.720)

0.887